Vascular Biogenics(VBLT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VBLT Vascular Biogenics

Market Closed 10-16 16:00:00 EDT

5.46

+0.00

0.00%

High5.46	Low5.46	Vol0.00
Open5.46	D1 Closing5.46	Amplitude0.00%
Mkt Cap12.11M	Tradable Cap9.00M	Total Shares2.22M
T/O968.74K	T/O Rate0.00%	Tradable Shares1.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"VBLT","market":"US","secType":"STK","nameCN":"Vascular Biogenics","latestPrice":5.46,"timestamp":1697486400000,"preClose":5.46,"halted":8,"volume":0,"delay":0,"floatShares":1647907,"shares":2218299,"eps":-7.16779,"marketStatus":"Market Closed","change":0,"latestTime":"10-16 16:00:00 EDT","open":5.46,"high":5.46,"low":5.46,"amount":968736.23409585,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-7.16779,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1735549200000},"marketStatusCode":7,"symbolChange":{"newSymbol":"NTBL","executeDate":"2023-10-17"},"adr":0,"adrRate":0,"listingDate":1412136000000,"exchange":"NASDAQ","adjPreClose":5.46,"volumeRatio":0},"requestUrl":"/m/hq/s/VBLT/tweets","defaultTab":"tweets","newsList":[{"id":"2376149817","title":"Notable Labs Shares Surged Over 80% after Closing Merger Transaction With VBL Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2376149817","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2376149817?lang=en_us&edition=fundamental","pubTime":"2023-10-17 16:45","pubTimestamp":1697532342,"startTime":"0","endTime":"0","summary":"- Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol “NTBL” effective at market open on October 17 -. - Aggregate net transaction proceeds expected to fund planned operations into 2025 -. - Completed previously announced $10.3 million private placement with leading healthtech-focused investors, led by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund -. - Predictive Precision Medicines Platform  applied to select and develop two clinical-stage therapeutic candidates with lead programs in acute myeloid leukemia ; four Phase 2 milestones expected by 1Q 2025 including Phase 2a results for lead asset Volasertib in adult AML in 3Q 2024 -. - Notable’s proprietary PPMP combines multi-dimensional biological assays and machine learning to bio-simulate a patient’s cancer treatment and predict their clinical response to the actual treatment -. Notable’s PPMP combines multi-dimensional biological assays and machine learning to bio-","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/notable-labs-closes-merger-transaction-170100326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","VBLT","NTBL"],"gpt_icon":0},{"id":"2374980029","title":"VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2374980029","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2374980029?lang=en_us&edition=fundamental","pubTime":"2023-10-12 21:00","pubTimestamp":1697115600,"startTime":"0","endTime":"0","summary":"Approved Merger with Notable Labs and All Other Proposals. Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions. MODI’IN, Israel and NEW YORK, Oct. 12, 2023  -- VBL Therapeutics  , today announced that its shareholders voted to approve the previously announced proposed merger  with Notable Labs, Inc. , at the annual and special meeting  which took place today, October 12, 2023.The Merger is expected to close on or around October 16, 2023. After completion of the Merger, VBL will be renamed “Notable Labs, Ltd.” and is expected to trade on The Nasdaq Capital Market under the symbol “NTBL” on or around October 17, 2023.Vascular Biogenics Ltd., operating as VBL Therapeutics , is a biopharmaceutical company that has historically focused on developing targeted therapies for cancer and immune-inflammatory diseases.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dq8HdJDi3ung72B5cQQLkg--~B/aD0xNTM4O3c9Mjg2MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/e5a5bc6669db9e35979562388a67fba0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dq8HdJDi3ung72B5cQQLkg--~B/aD0xNTM4O3c9Mjg2MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/e5a5bc6669db9e35979562388a67fba0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vbl-therapeutics-announces-results-annual-130000666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NTBL","QID","QQQ","TQQQ","QLD","PSQ","MNQmain","NQmain",".IXIC","BK4139","SQQQ","VBLT"],"gpt_icon":0},{"id":"2374454025","title":"Nano-X, InMode, Teva among notable Israel-based healthcare decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2374454025","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2374454025?lang=en_us&edition=fundamental","pubTime":"2023-10-10 01:00","pubTimestamp":1696870803,"startTime":"0","endTime":"0","summary":"Healthcare companies headquartered in Israel were trading lower in the U.S. on Monday after the country declared war on the Hamas organization, sparking a large-scale armed conflict in the Palestinian","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1713753449/image_1713753449.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1713753449/image_1713753449.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4019178-nano-x-inmode-teva-among-notable-israel-based-healthcare-decliners","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4584","ICCM","BK4585","CHEK","TEVA","ENLV","BK4559","CANF","BK4588","PYPD","BK4566","KMDA","BK4139","INCR","BK4082","BWAY","GMDA","BK4557","BK4007","CGEN","INMD","BK4121","MDWD","NNOX","VBLT"],"gpt_icon":0},{"id":"2374172175","title":"BUZZ-US-listed healthcare firms down amid Middle East conflict","url":"https://stock-news.laohu8.com/highlight/detail?id=2374172175","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2374172175?lang=en_us&edition=fundamental","pubTime":"2023-10-09 19:46","pubTimestamp":1696851973,"startTime":"0","endTime":"0","summary":"** Shares of U.S.-listed healthcare firms based in or with operations in Israel down 4%-12% premarket amid military conflict in the Middle East   ** U.S.-listed shares of Teva Pharmaceutical   , the world's largest generic drugmaker, drops 4%   ** Shares of Gamida Cell    down ~10%, Vascular Biogenics    slide 8.2%, IceCure Medical    fell 12.2%   ** Protalix BioTherapeutics    down 5.5% despite a statement saying it does not anticipate a disruption in supply of Elelyso, which treats a rare genetic disorder   ** Other U.S.-listed shares of healthcare firm such as BioLineRX   , InterCure   , Can-Fite BioPharma  are down nearly 7% ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","MDWD","BK4007","ICCM","VBLT","GMDA","BK4139","BUZZ"],"gpt_icon":0},{"id":"2372063879","title":"Press Release: VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2372063879","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2372063879?lang=en_us&edition=fundamental","pubTime":"2023-10-04 20:00","pubTimestamp":1696420800,"startTime":"0","endTime":"0","summary":"Shareholders of record as of September 5, 2023 are eligible to vote at the VBL Shareholder Meeting on October 12, 2023. If the relevant proposals at the Meeting are approved, the parties anticipate that the Merger will close within a few days thereafter, subject to the satisfaction of all other closing conditions. VBL Ordinary Shares are currently listed on The Nasdaq Capital Market under the symbol \"VBLT\". After completion of the Merger, VBL is expected to be renamed \"Notable Labs, Ltd.\" and trade on The Nasdaq Capital Market under the symbol \"NTBL\".The Meeting will take place on October 12, 2023, at 8:00 a.m. ET  and will be held:. -- at VBL's offices at 8 HaSatat St. Modi'in, Israel, and. -- in virtual format via live audio webcast accessible via a unique access. link shareholders will receive upon registering to attend the Meeting.If you have questions about the Merger, including the procedures for voting your shares, please contact:. Even if you plan to attend the Meeting via live","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VBLT"],"gpt_icon":0},{"id":"2372853261","title":"BRIEF-Vascular Biogenics - Following Execution Of Term Sheet With Wellbeing Group On June 30, Parties Negotiated A Definitive Asset Purchase Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2372853261","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2372853261?lang=en_us&edition=fundamental","pubTime":"2023-10-03 05:39","pubTimestamp":1696282740,"startTime":"0","endTime":"0","summary":"Oct 2  - Vascular Biogenics Ltd   :   * VASCULAR BIOGENICS-  FOLLOWING EXECUTION OF TERM SHEET WITH WELLBEING GROUP ON JUNE 30, PARTIES NEGOTIATED A DEFINITIVE ASSET PURCHASE AGREEMENT   * VASCULAR BIOGENICS-  DEFINITIVE ASSET PURCHASE AGREEMENT FOR SALE OF VB-601 AND MOSPD2 RELATED ASSETS   * VASCULAR BIOGENICS LTD - VBL ENTERED INTO ASSET PURCHASE AGREEMENT ON OCTOBER 1, 2023Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051017.SGD","LU1861220033.SGD","LU1861215975.USD","ON","BK4141","LU1720051108.HKD","LU1854103824.USD","LU1854104046.USD","BK4588","BK4512","LU0348723411.USD","LU2357305700.SGD","VBLT","LU1548497426.USD","BK4139","BK4585"],"gpt_icon":0},{"id":"2365968025","title":"Press Release: VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC","url":"https://stock-news.laohu8.com/highlight/detail?id=2365968025","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2365968025?lang=en_us&edition=fundamental","pubTime":"2023-09-06 20:00","pubTimestamp":1694001600,"startTime":"0","endTime":"0","summary":"VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC. Merger with Notable expected to close in mid-October, subject to shareholder approval. MODI'IN, Israel and NEW YORK, Sept. 06, 2023  -- VBL Therapeutics  , today announced that its registration statement on Form S-4 in connection with the proposed merger with Notable Labs, Inc.  has been declared effective by the U.S. Securities and Exchange Commission .\"Having our registration statement on Form S-4 declared effective by the SEC is an important step towards the closing of our previously announced merger with Notable,\" said Prof. Dror Harats, M.D., Chief Executive Officer of VBL. \"We believe this merger represents the best path forward for the shareholders of both companies and for patients. The combined organization is expected to be listed on Nasdaq, and plans to apply Notable's Predictive Precision Medicines Platform to develop a pipeline of clinical-stage pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VBLT"],"gpt_icon":0},{"id":"2359887588","title":"Vascular Biogenics Q2 EPS $(0.01) Up From $(0.12) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2359887588","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2359887588?lang=en_us&edition=fundamental","pubTime":"2023-08-14 20:24","pubTimestamp":1692015894,"startTime":"0","endTime":"0","summary":"Vascular Biogenics (NASDAQ:VBLT) reported quarterly losses of $(0.01) per share. This is a 91.67 percent increase over losses of $(0.12) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/23/08/33828768/vascular-biogenics-q2-eps-0-01-up-from-0-12-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VBLT"],"gpt_icon":0},{"id":"2359462880","title":"VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2359462880","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2359462880?lang=en_us&edition=fundamental","pubTime":"2023-08-14 20:00","pubTimestamp":1692014400,"startTime":"0","endTime":"0","summary":"Merger with Notable expected to close in late September or October, subject to VBL’s S-4 registration statement being declared effective and shareholder approval. $24.3 million in cash and cash equivalents as of June 30, 2023. MODI’IN, Israel and NEW YORK, Aug. 14, 2023  -- VBL Therapeutics  , today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update.“We continue to make good progress towards the closing of our previously announced merger with Notable,” said Prof. Dror Harats, M.D., Chief Executive Officer of VBL. “We believe the proposed merger represents the best path forward for the shareholders of both companies and for patients. The combined organization is expected to be listed on Nasdaq, and will apply Notable’s Predictive Precision Medicines Platform to develop a pipeline of clinical-stage precision medicines with the goal of transforming the standard of care in oncology. Our S-4 registration statement is currently under revie","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dq8HdJDi3ung72B5cQQLkg--~B/aD0xNTM4O3c9Mjg2MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/e5a5bc6669db9e35979562388a67fba0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dq8HdJDi3ung72B5cQQLkg--~B/aD0xNTM4O3c9Mjg2MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/e5a5bc6669db9e35979562388a67fba0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vbl-therapeutics-reports-second-quarter-120000396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","VBLT"],"gpt_icon":0},{"id":"2335819400","title":"BRIEF-Vbl Therapeutics Reports First Quarter 2023 Financial Results And Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2335819400","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2335819400?lang=en_us&edition=fundamental","pubTime":"2023-05-16 04:30","pubTimestamp":1684182647,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VBLT","BK4139"],"gpt_icon":0},{"id":"2335199308","title":"Vascular Biogenics Q1 EPS $(0.03) Beats $(0.15) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2335199308","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2335199308?lang=en_us&edition=fundamental","pubTime":"2023-05-16 04:24","pubTimestamp":1684182252,"startTime":"0","endTime":"0","summary":"Vascular Biogenics (NASDAQ:VBLT) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.15) by 80 percent. This is a 76.92 percent increase over losses of $(0.13) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/23/05/32406535/vascular-biogenics-q1-eps-0-03-beats-0-15-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VBLT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vblrx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0065},{"period":"1month","weight":-0.0064},{"period":"3month","weight":0.0412},{"period":"6month","weight":0.0933},{"period":"1year","weight":0.2482},{"period":"ytd","weight":0.2518}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.777778,"avgChangeRate":0.242918},{"month":2,"riseRate":0.555556,"avgChangeRate":-0.057068},{"month":3,"riseRate":0.555556,"avgChangeRate":-0.024127},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.044319},{"month":5,"riseRate":0.666667,"avgChangeRate":0.178369},{"month":6,"riseRate":0.555556,"avgChangeRate":-0.015963},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.100813},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.028826},{"month":9,"riseRate":0.555556,"avgChangeRate":0.060085},{"month":10,"riseRate":0.111111,"avgChangeRate":-0.091166},{"month":11,"riseRate":0.555556,"avgChangeRate":0.018497},{"month":12,"riseRate":0.222222,"avgChangeRate":-0.037298}],"exchange":"NASDAQ","name":"Vascular Biogenics","nameEN":"Vascular Biogenics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vascular Biogenics(VBLT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vascular Biogenics(VBLT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vascular Biogenics,VBLT,Vascular Biogenics股票,Vascular Biogenics股票老虎,Vascular Biogenics股票老虎国际,Vascular Biogenics行情,Vascular Biogenics股票行情,Vascular Biogenics股价,Vascular Biogenics股市,Vascular Biogenics股票价格,Vascular Biogenics股票交易,Vascular Biogenics股票购买,Vascular Biogenics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vascular Biogenics(VBLT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vascular Biogenics(VBLT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction